Hormonal factors and prognosis in epithelial ovarian cancer: a multivariate analysis.
When a significantly lower follicle stimulating hormone (FSH) level was found in patients with epithelial ovarian carcinoma, it was decided to analyze the influence of hormonal factors on prognosis. Thirteen factors were tested for prognostic significance in 35 women with epithelial ovarian carcinoma. Age, FIGO-stage, histopathological grade, residual tumor, treatment, gonadotrophins and steroid hormones were tested. By univariate log-rank testing a significantly shorter survival time was found for patients with ascending FIGO-stage, residual tumor mass, estradiol < 0.10 nmol/l, progesterone < 2.0 nmol/l and DHEAS < 1300 nmol/l. In the Cox model the independently significant prognostic factors found were residual tumor mass (P < 0.001) with a risk estimate of 2.65, progesterone (P < 0.05) with a risk estimate of 0.29 for a progesterone level > 2.0 nmol/l and total testosterone (P < 0.03) with a risk estimate of 0.29 for a total testosterone level > 1.15 nmol/l. The present findings, together with the assumption that an elevated gonadotrophin level may induce ovarian tumor growth (the gonadotrophin theory), earlier findings of estrogen and progesterone receptors in human ovarian cancer, and the in vitro demonstration of gonadotrophin-growth-stimulation of human malignant epithelial tumors, justify a thorough investigation of the interaction between steroid hormones and receptors, gonadotrophins, tumor bulk and survival in future research protocols.
Blaakaer
J
J
Dept. of Obstetrics and Gynecology, Rigshospitalet, Copenhagen, Denmark.
Høgdall
C K
CK
Hørding
U
U
Bennett
P
P
Toftager-Larsen
K
K
Daugaard
S
S
Bock
J
J
D000230:Adenocarcinoma / Q000097:blood / Q000473:pathology / Q000628:therapy; D018262:Adenocarcinoma, Clear Cell / Q000097:blood / Q000473:pathology / Q000628:therapy; D002288:Adenocarcinoma, Mucinous / Q000097:blood / Q000473:pathology / Q000628:therapy; D000375:Aging; D000735:Androstenedione / Q000097:blood; D018269:Carcinoma, Endometrioid / Q000097:blood / Q000473:pathology / Q000628:therapy; D018284:Cystadenocarcinoma, Serous / Q000097:blood / Q000473:pathology / Q000628:therapy; D003687:Dehydroepiandrosterone / Q000031:analogs & derivatives / Q000097:blood; D019314:Dehydroepiandrosterone Sulfate; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006728:Hormones / Q000097:blood*; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000097:blood* / Q000473:pathology / Q000628:therapy; D011374:Progesterone / Q000097:blood; D011379:Prognosis; D012044:Regression Analysis; D013739:Testosterone / Q000097:blood
D006728:Hormones; D013739:Testosterone; D000735:Androstenedione; D003687:Dehydroepiandrosterone; D011374:Progesterone; D004958:Estradiol; D019314:Dehydroepiandrosterone Sulfate; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone